Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method
暂无分享,去创建一个
P C Lambert | Nicholas R Latimer | M J Crowther | K R Abrams | N. Latimer | R. Akehurst | K. Abrams | A J Wailoo | J P Morden | R L Akehurst | M J Campbell | J. Morden | MJ Crowther | Pc Lambert | MJ Campbell | AJ Wailoo | M. Crowther
[1] David J. Lunn,et al. Survival extrapolation using the poly-Weibull model , 2015, Statistical methods in medical research.
[2] Xin Huang,et al. Adjusting overall survival for treatment switches: commonly used methods and practical application , 2013, Pharmaceutical statistics.
[3] S. Cole,et al. Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. , 2011, American journal of epidemiology.
[4] J H Ellenberg,et al. Analysis of clinical trials by treatment actually received: is it really an option? , 1991, Statistics in medicine.
[5] R. Horwitz,et al. Adherence to treatment and health outcomes. , 1993, Archives of internal medicine.
[6] Ian R. White,et al. Impact of treatment changes on the interpretation of the Concorde trial , 1996, AIDS.
[7] Keith R Abrams,et al. Flexible parametric joint modelling of longitudinal and survival data , 2012, Statistics in medicine.
[8] Patrick Royston,et al. The design of simulation studies in medical statistics , 2006, Statistics in medicine.
[9] J. Robins,et al. Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .
[10] J. Robins,et al. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. , 1993, Controlled clinical trials.
[11] J. Robins,et al. Adjusting for differential rates of prophylaxis therapy for PCP in high- versus low-dose AZT treatment arms in an AIDS randomized trial , 1994 .
[12] Y. Ohashi,et al. Adjusting for differential proportions of second‐line treatment in cancer clinical trials. Part II: An application in a clinical trial of unresectable non‐small‐cell lung cancer , 2004, Statistics in medicine.
[13] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[14] K. Abrams,et al. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study , 2011, BMC medical research methodology.
[15] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[16] I. White. Uses and limitations of randomization-based efficacy estimators , 2005, Statistical methods in medical research.
[17] Abdel Babiker,et al. strbee: Randomization-based Efficacy Estimator , 2002 .
[18] Ralf Bender,et al. Generating survival times to simulate Cox proportional hazards models , 2005, Statistics in medicine.
[19] Keith R. Abrams,et al. Joint Modeling of Longitudinal and Survival Data , 2013 .
[20] James M. Robins,et al. Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .
[21] M. Hoyle,et al. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. , 2009, Health Technology Assessment.
[22] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[23] P. Tappenden,et al. Methodological issues in the economic analysis of cancer treatments. , 2006, European journal of cancer.
[24] Ian R. White,et al. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.
[25] J. Robins,et al. Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .
[26] J. Robins. Structural Nested Failure Time Models , 2005 .
[27] Y. Ohashi,et al. Adjusting for differential proportions of second‐line treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects , 2004, Statistics in medicine.
[28] J. Robins. Analytic Methods for Estimating HIV-Treatment and Cofactor Effects , 2002 .
[29] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.
[30] Michael J Crowther,et al. Simulating biologically plausible complex survival data , 2013, Statistics in medicine.
[31] J. Whitehead,et al. Estimating a treatment effect in survival studies in which patients switch treatment , 2002, Statistics in medicine.
[32] J. Sterne,et al. G-estimation of Causal Effects, Allowing for Time-varying Confounding , 2002 .